scholarly journals Effect of Photopheresis on Lymphocyte Population in Children with Newly Diagnosed Type 1 Diabetes

2004 ◽  
Vol 11 (5) ◽  
pp. 856-861 ◽  
Author(s):  
J. Ernerudh ◽  
J. Ludvigsson ◽  
G. Berlin ◽  
U. Samuelsson

ABSTRACT In recent years photopheresis has been claimed to be an effective form of immunomodulation. It has also been shown to have an effect on the disease process at the onset of type 1 diabetes. In a double-blind, placebo-controlled randomized study, we analyzed if the effect of photopheresis in children with newly diagnosed diabetes is related to changes in the balance of lymhocyte populations. We also analyzed if lymphocyte subsets were related to recent infection, mild or aggressive disease manifestations, heredity, or gender. Nineteen children received active treatment with photopheresis, while 21 children received sham pheresis (placebo group). No influence of a history of previous infection, heredity, or certain clinical parameters on lymphocyte subsets was found. At the onset of type 1 diabetes, girls showed a higher proportion and a larger number of T cells (CD3+) and T-helper cells (CD4+) and a higher proportion of naïve CD4+CD45RA+ cells. In the placebo group, an increase in the number of subsets with the activated phenotype in both the CD4 (CD29+) and the CD8 (CD11a+) compartments was noted during the course of the study. These changes did not occur in the photopheresis group. No relation between lymphocyte subsets and clinical outcome was found 1 year after the treatment with photopheresis. In conclusion, we found no major effect of photopheresis on lymphocyte populations in a group of children with newly diagnosed type 1 diabetes. However, in the placebo group the proportions of activated CD4 and CD8 cells increased over time. Since these changes did not occur in the actively treated group, our findings suggest that photopheresis may have some suppressive effects.

Author(s):  
Κ. Kądziela ◽  
Η. Kowalska ◽  
Β. Rymkiewicz-Kluczynska ◽  
Μ. Kowalska ◽  
G. Miszkurka ◽  
...  

BMJ Open ◽  
2017 ◽  
Vol 7 (10) ◽  
pp. e017178 ◽  
Author(s):  
Lidia Groele ◽  
Hania Szajewska ◽  
Agnieszka Szypowska

IntroductionRecent evidence has demonstrated that, among other factors, dysbiosis (imbalances in the composition and function of the gut microbiota) may be relevant in the development of type 1 diabetes (T1D). Thus, gut microbiota may be a target for improving outcomes in subjects with T1D. The aim of the study is to examine the effects ofLactobacillus rhamnosusGG andBifidobacterium lactisBb12 on beta-cell function in children with newly diagnosed T1D.Methods and analysisA total of 96 children aged 8 to 17 years with newly diagnosed T1D, confirmed by clinical history and the presence of at least one positive autoantibody, will be enrolled in a double-blind, randomised, placebo-controlled trial in which they will receiveL. rhamnosusGG andB. lactisBb12 at a dose of 109colony-forming units or an identically appearing placebo, orally, once daily, for 6 months. The follow-up will be for 12 months. The primary outcome measures will be the area under the curve of the C-peptide level during 2-hour responses to a mixed meal.Ethics and disseminationThe Bioethics Committee approved the study protocol. The findings of this trial will be submitted to a peer-reviewed paediatric journal. Abstracts will be submitted to relevant national and international conferences.Trial registration numberNCT03032354; Pre-results.


2003 ◽  
pp. 323-329 ◽  
Author(s):  
S Sarnblad ◽  
M Kroon ◽  
J Aman

OBJECTIVE: Metabolic control often deteriorates during puberty in children with type 1 diabetes. The aim of the present study was to investigate whether addition of metformin for 3 Months improves metabolic control and insulin sensitivity. DESIGN: Twenty-six of 30 randomised adolescents with type 1 diabetes (18 females, eight males) completed a double-blind placebo-controlled trial. Their mean age was 16.9+/-1.6 (s.d.) Years, mean glycated haemoglobin (HbA(1c)) 9.5+/-1.1% and daily insulin dosage 1.2+/-0.3 U/kg. The participants were randomised to receive oral metformin or placebo for 3 Months. HbA(1c) was measured Monthly, and peripheral insulin sensitivity was assessed by a euglycaemic hyperinsulinaemic clamp at baseline and at the end of the study. RESULTS: HbA(1c) decreased significantly in the group treated with metformin, from 9.6 to 8.7% (P<0.05), but was unchanged in the placebo group (9.5 vs 9.2%). Peripheral glucose uptake divided by mean plasma insulin concentration was increased in the metformin group (P<0.05) but not in the placebo group. Initial insulin sensitivity was inversely correlated to changes in HbA(1c) (r=-0.62; P<0.05) and positively correlated to changes in insulin sensitivity (r=0.77; P<0.01). CONCLUSIONS: In this double-blind placebo-controlled study we found that metformin improves metabolic control in adolescents with type 1 diabetes. The effect seems to be associated with an increased insulin-induced glucose uptake.


1988 ◽  
Vol 24 (2) ◽  
pp. 118-121
Author(s):  
F. CHIARELLI ◽  
A. BLASETTI ◽  
A. VERROTTI ◽  
M. ANICHINI ◽  
G. MORGESE

2014 ◽  
Author(s):  
Sarah Kiff ◽  
Ailish Nimmo ◽  
Kathryn Noyes ◽  
Louise Bath

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1278-P
Author(s):  
IMAN AL-GADI ◽  
RANDI STREISAND ◽  
MAUREEN MONAGHAN ◽  
CARRIE TULLY ◽  
MANUELA SINISTERRA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document